Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany
Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including <i>Candida parapsilosis</i>) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.
Authors
- Filippo Trapani (ORCID: https://orcid.org/0009-0003-6541-9435)
- Giusy Tiseo (ORCID: https://orcid.org/0000-0002-3884-4933)
- Giulio Viceconte (ORCID: https://orcid.org/0000-0003-3989-2520)
- Elham Khatamzas (ORCID: https://orcid.org/0000-0001-9253-1340)
- Valentina Morena
- Giovanni Mori (ORCID: https://orcid.org/0000-0003-0399-2220)
- Britta Kölking
Institutions
- University of Pisa (IT)
- Vita-Salute San Raffaele University (IT)
- Heidelberg University (DE)
- Fairfield Infectious Diseases Hospital (AU)
- University Hospital Heidelberg (DE)
- Provincia Autonoma di Trento (IT)
- Alessandro Manzoni Hospital (IT)
- German Center for Infection Research (DE)
- Azienda USL di Bologna (IT)
- Guglielmo da Saliceto Hospital (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Aziende Socio Sanitarie Territoriali di Lecco
- University of Naples Federico II (IT)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1093/ofid/ofaf034
- Citations
- 9
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 12.57
Funders
- Mundipharma Research Limited